Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.23M Sell
13,686
-1,481
-10% -$142K 0.01% 781
2025
Q4
$1.41M Sell
15,167
-9,049
-37% -$986K 0.02% 647
2025
Q3
$3.02M Buy
24,216
+9,246
+62% +$1.18M 0.04% 483
2025
Q2
$1.97M Buy
14,970
+86
+0.6% +$9.73K 0.03% 580
2025
Q1
$1.56M Sell
14,884
-5,503
-27% -$576K 0.02% 627
2024
Q4
$2.21M Buy
20,387
+765
+4% +$85.5K 0.03% 509
2024
Q3
$2.1M Sell
19,622
-760
-4% -$76.9K 0.03% 541
2024
Q2
$2.02M Buy
20,382
+5,352
+36% +$539K 0.03% 530
2024
Q1
$1.39M Sell
15,030
-15,538
-51% -$1.25M 0.02% 626
2023
Q4
$2.31M Buy
30,568
+14,573
+91% +$948K 0.04% 458
2023
Q3
$969K Sell
15,995
-200
-1% -$13.7K 0.02% 687
2023
Q2
$1.17M Sell
16,195
-300
-2% -$19K 0.02% 643
2023
Q1
$915K Sell
16,495
-363
-2% -$20K 0.02% 723
2022
Q4
$854K Sell
16,858
-324
-2% -$16K 0.02% 739
2022
Q3
$724K Buy
+17,182
New +$856K 0.02% 760
2021
Q3
Sell
-3,104
Closed -$310K 1534
2021
Q2
$310K Sell
3,104
-97
-3% -$9K 0.01% 1227
2021
Q1
$284K Buy
3,201
+35
+1% +$3.46K 0.01% 1204
2020
Q4
$304K Buy
+3,166
New +$243K 0.01% 1076

Other funds holding ITRI

Oppenheimer & Co's ITRI Position: Q1 2026 in Review

Oppenheimer & Co reduced its Itron (ITRI) stake by 9.8% in Q1 2026, selling an estimated $142K and leaving 13,686 shares worth $1.23M. The position accounts for 0.01% of the portfolio, ranked #781.

Oppenheimer & Co first reported a position in ITRI in Q4 2020 and has held it in 18 quarters since. The position peaked at $3.02M in Q3 2025. 432 funds tracked by Wall St. Rank hold ITRI as of Q1 2026.

  • Oppenheimer & Co held 13,686 shares of Itron worth $1.23M as of Q1 2026.
  • Oppenheimer & Co sold 1,481 Itron shares in Q1 2026, an estimated $142K.
  • Itron made up 0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #781 holding.
  • Oppenheimer & Co first reported a position in Itron in Q4 2020 and has held it in 18 quarters since.
  • Oppenheimer & Co's Itron position peaked at $3.02M in Q3 2025.
  • 432 funds tracked by Wall St. Rank held Itron as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.